Is cancer, the terror of the whole world, now on the verge of eradication? With that possibility, the first-ever cancer vaccine has been applied to the human body. Researchers there have claimed that the initial results of this vaccine in the treatment of melanoma (skin cancer) made in Russia are very promising. It has been claimed that the patient who received the vaccine is healthy. And the necessary immunity has been developed in his body to fight cancer.
The company that produces this innovative vaccine in the fight against cancer is the Gamaleya Research Institute. Alexander Ginzburg, head of the scientific team of the organization, told Russian media that the patient who was administered this vaccine is currently healthy and normal. His body is showing positive effects. The patient’s body is producing such active ingredients that will help the patient fight the tumor and its metastasis. The whole situation is very promising after the first administration of the vaccine.
The head of the scientific team, Alexander Ginzburg, told Russian media that the patient who received the vaccine is currently healthy and normal. He is showing positive effects.
It is worth noting that last year, the Russian Ministry of Health approved two domestically developed cancer treatments. One of them is the mRNA-based vaccine ‘NeoOncoVac’ for advanced melanoma. The other is the peptide-based drug ‘OncoPept’ for colorectal cancer or stomach cancer. In April this year, NeoOncoVac was administered to humans for the first time. It was administered to a 60-year-old man.
The man was in the third stage of melanoma cancer, which was rapidly spreading to other parts of his body. The patient is currently undergoing treatment at the Herzen Oncology Research Institute in Moscow. Ginzburg said the patient will be given two more doses of the vaccine. His immunity will be monitored throughout the treatment process. Vaccines are being prepared separately for 10 more patients besides this patient. Ginzburg said they will be ready in the next one and a half to three months.